Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Biodefense Market Overview

Biodefense Market size was valued at USD 15.83 billion in 2023. The Biodefense Market industry is projected to grow from USD 16.74 Billion in 2024 to USD 26.89 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.01% during the forecast period (2024 - 2032).

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Biodefense Market Trends

Increasing government initiatives and funding

Governments are spending a lot of money on vaccine research and development to be ready for any bioterrorism attacks. Government efforts to be ready for any form of bioterrorism have created enormous opportunities for pharmaceutical companies operating in the biodefense market to expand. Moreover, governments worldwide are implementing initiatives to enhance biodefense capabilities. Increased funding for research and development, preparedness planning, infrastructure development, and procurement of vaccines and medications drives the growth of the biodefense market.

• The World Health Organisation (WHO), the United Nations Children's Fund (UNICEF), and the International Federation of Red Cross and Red Crescent Societies (IFRC) announced the creation of a global Ebola vaccine stockpile in January 2021. This will allow countries to contain future Ebola outbreaks by ensuring timely access to vaccines through the assistance of humanitarian organisations.


• Thailand developed a national strategic plan for bioterrorism preparedness and response, which includes the establishment of a bioterrorism surveillance system, laboratory and epidemiological surveillance capacity building, and bioterrorism response training for medical personnel.

Biodefense Market Segment Insights

Biodefense Disease Type Insights

The Biodefense Market segmentation, based on disease type, includes anthrax, small pox, botulism, influenza, radiation/nuclear, and others. The anthrax segment held the majority share in 2023 of the Biodefense Market revenue. This is due to rising concerns about biological weapon use, and growing animal exposure incidents. Moreover, anthrax is known for its potential as a biological weapon due to the durability and resistance of its spores. The disease can be transmitted to humans through direct contact with infected animals or their products, such as wool, hides, or meat. It can also be contracted by inhaling or ingesting the spores or through intentional exposure in a bioterrorism attack.

Biodefense Treatment Insights

The Biodefense Market segmentation is based on treatment that include vaccination, and medication. vaccination segment is projected to be the faster-growing segment during the forecast period. This is attributed to the increasing threat of emerging infectious diseases, rising development of novel pathogens, and increasing global immunization initiatives.

BIODEFENSE MARKET SIZE, BY TREATMENT, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

July 2022: Bavarian Nordic announced that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by the vaccinia virus.

Biodefense Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Biodefense market accounted for the largest market share in 2023. This is due to the rise in the prevalence of infectious diseases such as influenza, viral hepatitis, and HIV in the region. For Instance, according to the Centers for Disease Control and Prevention (CDC) in 2021, It was estimated that around 9 million people are diagnosed with the Influenza virus in the US and this trend is expected to further increase with the rise of antimicrobial resistance. Additionally, the rising demand for affordable diagnostic tests, vaccines, and therapeutics to combat such infectious diseases is expected to drive the market.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: BIODEFENSE MARKET SIZE, BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe Biodefense market accounts for the second-largest market share due to prevalence of chronic disease and the rise in research and development activities for biodefense solutions across the region. further, Germany Biodefense market was attributed to hold the largest market share, and the Rest of Europe Biodefense market is expected to fastest-growing market in the European region.

The Asia-Pacific Biodefense market is expected to grow at a significant share from 2023 to 2032. This is due to the increase in prevalence of patient population across the region is the key factor driving the growth of the market. An increase in the number of reported infections of communicable diseases and extensive outbreaks of infectious diseases such as influenza, Covid-19 and others are posing a serious health risk to consumers in the region. Moreover, Japan Biodefense market is expected to hold the largest market share, and Rest of Asia-Pacific Biodefense market is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World is segmented into the Middle East, Africa, and Latin America. The Biodefense market in the above-mentioned regions is likely to witness growth due to an increase in the prevalence of infectious diseases such as Covid-19, influenza, and others. For instance, according to National center of Biotechnology information in 2023, it was estimated about 38 million are diagnosed with COVID-19 in Brazil. Thus, rise in the prevalence of infectious disease has led to an increase in the demand of biodefense solution across the region which drives the growth of market.

Biodefense Key Market Players & Competitive Insights

The Biodefense Market is characterized by the presence of many global, regional, and local vendors. Developments in the healthcare industry and growing research and development make the Biodefense market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

Emergent is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). Its solutions include product portfolio, products that are under development (pipeline products), and contract development and manufacturing (“CDMO”). Revenues are generated by the sale and procurement of the company's product/product candidate portfolio, the provision of CDMO services to external customers, and non-dilutive contract and grant funding for research and development ("R&D") projects from various third-party sources.

Key Companies in the Biodefense Market include

• Emergent (US)


• Novavax, Inc. (US)


• Fabentech Biotech (France)


• SIGA Technologies (US)


• Dynavax Technologies (US)


• Altimmune (US)


• Bavarian Nordic (Denmark)


• Elusys Therapeutics, Inc. (US)


• Cleveland Biolabs, Inc. (US)


• Ology Bioservices (US)

Biodefense Industry Developments

February 2023: Novavax, Inc. and U.S. Government extended their partnership and deliver up to 1.5 million doses of the Novavax vaccine. The contract has been supported through previously federal monies from Health and Human Services (US), the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority, administered by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense.

Biodefense Market Segmentation

Biodefense Disease Type Outlook

• Anthrax


• Small Pox


• Botulism


• Influenza


• Radiation/Nuclear


• Others

Biodefense Treatment Outlook

• Vaccination


• Medication

Biodefense Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Rest of the World




• Middle East


• Africa


• Latin America

Report Attribute/Metric	Details
Market Size 2023	USD 15.83 billion
Market Size 2024	USD 16.74 billion
Market Size 2032	USD 26.89 billion
Compound Annual Growth Rate (CAGR)	7.01% (2024-2032)
Base Year	2023
Forecast Period	2024-2032
Historical Data	2019 to 2022
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Disease Type, and Treatment
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Key Companies Profiled	Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US)
Key Market Opportunities	Technological advancement
Key Market Dynamics	·  Increasing government initiatives and funding ·         Rise in demand for vaccines